The FDA approved Pfizer’s Talzenna (talazoparib) for treatment of certain forms of breast cancer.
The drug is indicated for treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. Patients must be selected based on an FDA-approved companion diagnostic.
The agency based its approval on the results of a 431-patient trial. The most common adverse reactions to the drug included fatigue, anemia, headache, decreased appetite and hair loss.